Effects of Propofol on Oxidative Stress and Liver Regeneration After Partial Hepatectomy

June 25, 2012 updated by: Rennes University Hospital

Prospective, Randomized, Simple Blind Study Comparing the Effects of an Anaesthesia With Propofol to an Anaesthesia With Desflurane on Oxydative Stress and Liver Function Recovery After Hepatectomy

Propofol is an anaesthetic agent that showed in vitro and in vivo anti oxidant properties. No data are available concerning the potential benefit of a total anaesthesia with propofol in partial hepatic surgery. Patients who undergo partial hepatic resection have frequent liver insufficiency that could be related in part to the oxidative stress induced by clamping the hepatic vessels during the surgical intervention. Our hypothesis is that propofol, by increasing liver resistance to this ischemia-reperfusion phenomenon, could improve the remaining liver function recovery, and therefore could reduce post surgical morbidity.

The aim of the study is to evaluate the anti oxidant effects of propofol compared to another widely used anaesthetic agent, inhaled desflurane, during and after partial hepatic resection with hepatic vessels clamping. The primary endpoint will be the level of malondialdehyde (a plasmatic marker of oxidative stress), 30 minutes after the end of hepatic clamping.

Study Overview

Status

Completed

Conditions

Detailed Description

Propofol is an anaesthetic agent that showed in vitro and in vivo anti oxidant properties. No data are available concerning the potential benefit of a total anaesthesia with propofol in partial hepatic surgery. Patients who undergo partial hepatic resection have frequent liver insufficiency that could be related in part to the oxidative stress induced by clamping the hepatic hilum during the surgical intervention. Our hypothesis is that propofol, by increasing liver resistance to ischemic-reperfusion injury, could improve the remaining liver function recovery, and therefore could reduce post surgical morbidity.

The aim of the study is to evaluate the anti oxidant effects of propofol compared to another widely used anaesthetic agent, inhaled desflurane, during and after partial hepatic resection with hepatic hilum clamping.

The primary endpoint will be the level of malondialdehyde (a plasmatic marker of oxidative stress), 30 minutes after the end of hepatic clamping.

The evolution over time of other markers of oxidative stress will be studied (glutathione, myeloperoxidase, nitric oxide), as well as functional and biological markers of liver regeneration.

Study Type

Interventional

Enrollment (Actual)

34

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Rennes, France, 35033
        • Surgical Intensive Care Unit - Rennes University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients over 18
  • Need for partial hepatic resection requiring heptic clamping
  • Resection of 4 liver segments or less
  • In case of cirrhosis, child A
  • Written informed consent

Non-inclusion Criteria:

  • Hemochromatosis
  • chemotherapy in the previous week before inclusion
  • Thrombosis of the portal vein or the hepatic artery
  • Absence of contraception among fertil woman
  • Concomitant treatment that could have potential interaction with propofol
  • Concomitant treatment known to have antioxidant properties
  • Inclusion in another study protocol using a medication incompatible with the present study
  • Patient in which the follow up seems impossible

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1
Anesthesic induction and maintenance with intravenous propofol.
  • Induction : intravenous propofol aiming a concentration of 4 to 8 µg/ml
  • Maintenance : intravenous propofol aiming a concentration of 3 to 6 µg/ml
Active Comparator: 2
Anesthesic induction with intravenous penthotal and maintenance with inhaled desflurane.
Intravenous penthotal at the dose of 3 to 5 mg/kg
Inhaled desflurane aiming an alveolar concentration of 4 to 6 per cent.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Plasma MDA levels
Time Frame: 30 minutes after the end of hepatic clamping
30 minutes after the end of hepatic clamping

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Kinetics of post surgical biological hepatic function recovery
Time Frame: Days 1, 2, 5, 10
  • Gamma gluatamyltransferase
  • ASAT
  • ALAT
  • Factor V
  • AlfagluthationeS-transferase
Days 1, 2, 5, 10
Kinetics of post surgical hepatic function recovery
Time Frame: Day 2
Monoethylglycinexylidide (MEGX) test
Day 2
Other biological markers of oxidative stress
Time Frame: Days 1 and 2
  • Glutathione
  • Myeloperoxidase
  • Nitric oxide
Days 1 and 2
Hemodynamics during and after surgery
Time Frame: Days 1 and 2
  • Mean arterial pressure
  • Heart rate
  • Diuresis
Days 1 and 2
Surgery related complications
Time Frame: 10 days
  • Liver insufficiency
  • Hepato renal syndrome
  • Local infections
10 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Yannick Malledant, MD, Rennes University Hospital
  • Study Chair: Bruno Laviolle, MD, Rennes University Hospital
  • Principal Investigator: David Aguillon, MD, Rennes University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2004

Primary Completion (Actual)

March 1, 2006

Study Completion (Actual)

March 1, 2006

Study Registration Dates

First Submitted

September 13, 2005

First Submitted That Met QC Criteria

September 13, 2005

First Posted (Estimate)

September 22, 2005

Study Record Updates

Last Update Posted (Estimate)

June 26, 2012

Last Update Submitted That Met QC Criteria

June 25, 2012

Last Verified

June 1, 2012

More Information

Terms related to this study

Other Study ID Numbers

  • AFSSAPS 040366
  • PHRC/03-02 (Other Identifier: Rennes University Hospital)
  • CIC0203/026

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatectomy

Clinical Trials on Propofol

3
Subscribe